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Superior Intensity and Reproducibility of SHU·454, a New Right
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MIKEL D. SMITH, MD, 01 LING KWAN, BS, H. JOSEPH REISER, PhD,
ANTHONY N. DeMARIA, MD, FACC
Lexington. Kentucky
Intravenous injection of a variety of fluids has been shown
to produce right heart contrast by ultrasound, but the
intensity and reproducibility achieved are variable. Thus,
a new polysaccharide agent being developed for com-
mercial distribution, SHU-454, was quantitatively com-
pared for intensity and variability with agitated saline
solution, indocyanine green, carbon dioxide and hydro-
gen peroxide. Videodensitometry was used to measure
peak and total opacification of the right ventricle after
peripheral intravenous contrast administration. One
hundred eighty injections were performed in nine closed
chest dogs while two-dimensional echograms were re-
Contrast echocardiography was introduced in 1968, when
Gramiak and Shah (I) first noted the ultrasonic appearance
of a "cloud of bubbles" during catheter flushes in the aortic
root. Subsequently, contrast has been visualized in the right
heart chambers after peripheral venous injection of a variety
of fluids (2,3). Thus far, this technique has been applied to
echographic identification of cardiac chambers and great
vessels, to establish the presence of valvular regurgitation,
and to identify the presence and direction of intracardiac
shunts (4-8).
A number of agents have been used in experimental an-
imals and human patients to produce ultrasonic contrast,
including agitated saline solution, indocyanine green, ether,
whole blood, hydrogen peroxide, carbon dioxide, Reno-
grafin and dextrose solutions (3,9-11). However, the in-
tensity and duration of the ultrasonic right heart opacification
produced by such agents by way of venous injection have
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corded. SHU-454 yielded the highest peak (p < 0.001)
and total (p < 0.005) intensity values when compared
with the standard agents. In addition, SHU-454 yielded
the lowest coefficient of variation between injections
(p < 0.04) in producing this contrast effect. There were
no biologically significant changes in heart rate, blood
pressure or arterial blood gases during injection of any
of the substances used. A newly developed agent, SHU-
454, is superior to standard agents in the ability to re-
liably produce right heart contrast after venous injection
in dogs.
not been quantitatively compared. Recently, a new poly-
saccharide ultrasonic contrast agent, SHU-454, has been
developed and introduced into evaluation for future com-
mercial distribution. Therefore, this study was performed
to evaluate the amplitude and reproducibility of right heart
opacification produced by the standard ultrasonic contrast
agents compared with SHU-454 after peripheral intravenous
injection in dogs. Furthermore, we assessed the hemody-
namic and physiologic effects produced by intravascular
injection of each of these contrast materials.
Methods
Experimental preparation. Studies were performed in
nine mongrel dogs anesthetized with sodium pentobarbital
(approximately 27 mg/kg intravenously) and ventilated with
15 mllkg room air at 15 to 25 breaths/min by a Harvard
ventilator and endotracheal tube. Core temperature was
monitored with a rectal temperature probe and the temper-
ature maintained at 38 ± 2°C with a heating pad. An 8
French angiographic catheter was inserted by cutdown into
the right femoral artery and advanced to the descending
aorta for monitoring arterial pressures and obtaining blood
gases. Pressures were measured with Statham P23-Db pres-
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Figure 1. Diagram of injection apparatus used in all nine dogs.
Contact was never broken between flush syringe and stopcock.
Design allows for purging the tubing between injections and pre-
vents the introduction of visible bubbles into the system.
and resolution. After the original baseline recordings in each
animal, no further changes were made in gray scale, depth,
power, damping or reject controls. During echocardio-
graphic study, care was taken to clearly visualize all en-
docardial surfaces and keep a constant transducer position
to include the right atrium, tricuspid valve, right ventricle
and apex in each recording. Recordings were begun before
injection and continued until contrast disappeared from the
right heart chambers.
Contrast agents. Five different echogenic contrast agents
were evaluated in quantities customarily used in clinical
studies: agitated saline solution, indocyanine green, hydro-
gen peroxide, carbon dioxide and SHU-454. In each in-
stance, standard 0.9% saline solution was used as a flush.
The total volume injected (contrast agent and flush solution)
was held constant at 10.5 ml. A 2.5 ml volume of 0.9%
saline solution was manually agitated with air; then all vis-
ible bubbles were removed before injection. A bolus injec-
tion of 8 ml of saline solution was used as flush. Indocyanine
green (Cardio-Green) in a standard solution of 2.5 mg/ml
was reconstituted before injection of 2.5 ml aliquots fol-
lowed by 9 ml bolus injection of saline flush. Hydrogen
peroxide, 1.0 ml of 3% standard stock solution, was fol-
lowed by a 9.5 ml bolus flush of saline solution. Carbon
dioxide was obtained from a storage tank under compres-
sion, and a 2.5 ml bolus of the gas was injected followed
by an 8 ml saline flush. SHU-454 powder was mixed with
5 ml saccharide diluent to form a 350 mg/ml solution, and
2.5 ml of this solution was followed by a slow flush of 8
ml saline solution delivered at 1.3 mils or less. All injections
were performed within 4 minutes of mixing.
Four injections of each agent were performed on every
dog. The order of agents used was changed with each an-
imal. After each injection, the intravenous line was cleared
of any residual contrast agent by withdrawing and discarding
10 to 20 ml of saline solution from the reservoir bag through
the tubing.
Videodensitometry. To more accurately quantify con-
trast effect, videodensitometric analysis was performed on
each videotaped injection by means of a unit custom made
at the University of Kentucky. The unit is an analog vi-
deodensitometer that has as its output signal the summation
of the voltage peaks from the rastor lines of the monitor
contained within an operator-adjusted sample volume. The
sample volume could be varied both in size and geometry
but was not altered after an optimal configuration was es-
tablished for each animal. The optical density of the echo-
cardiographic screen was calibrated from 0 to 1,000 mV
using the gray scale bars on the echographic screen. To
avoid problems with incomplete mixing and streaming within
the right atrium, the area of intensity sampled was the mid-
right ventricular cavity. Optical density was recorded be-
fore, during and after each injection, producing a curve (Fig.










sure transducers. Aortic pressures and a limb lead electro-
cardiogram were continuously monitored and recorded dur-
ing injections on a physiologic multichannel recorder (Gould,
model 2400). A 16 gauge 1.5 inch (3.8 cm) plastic cannula
was inserted into the right femoral vein for administration
of fluids and medications. A standard 2 inch (5 cm) 18
gauge plastic cannula was inserted into a left foreleg vein
percutaneously and this venous line served as injection site
for all contrast agents. The intravenous catheter was con-
nected to a maxidrip reservoir bag by a three way stopcock
and a 2.5 ml Travenol extension tube (Fig. I). To minimize
the possibility of extraneous bubble formation, contact was
not broken between tubing and flush syringe between in-
jections. Care was also taken to flush the tubing before
changing contrast agents and create fluid-fluid interfaces
without visible bubbles. Arterial blood samples were ob-
tained at baseline and after injection of each agent and were
analyzed for arterial pH, partial pressure of oxygen (Po])
and partial pressure of carbon dioxide (Peo2) by standard
techniques with a Micro-13 Blood Gas Analyzer (Instru-
mentation Laboratories), which was calibrated daily.
Two-dimensional echocardiographic examination. Two-
dimensional echocardiographic studies were performed uti-
lizing a mechanical ultrasonic sector scanner (ATL-Mark
500) with a 3.0 MHz transducer that yielded images at 30
frames/s over an 80° sector arc. Echocardiographic exam-
ination was performed with the dog in slight left lateral
decubitus position. Images were obtained with the trans-
ducer positioned at the point of maximal cardiac impulse
and oriented to obtain a four chamber view of the heart,
depicting the intracavitary area of both atria and both ven-
tricles. All injections were recorded on 0.5 inch (1.27 cm)
videotape for subsequent playback and analysis in real-time,
slowmotion, or by single frame. The audio channel was
utilized to indicate the specific contrast agent injected.
Two-dimensional echocardiograms were recorded in the
control state and the images adjusted for optimal contrast
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Figure 2. Videodensitometric curve obtained after
injection of SHU-454. Vertical axis represents
brightness (intensity) measured in millivolts (mV)
appearing in mid-right ventricle. Horizontal axis
represents time in seconds. Peak intensity (mV) is
measured at the highest point on the curve, while
total intensity (mV/s) is the integrated area under
the curve.
over time. To compare the contrast intensity, duration and
reproducibility of the individual agents, the videodensito-
metric tracings were measured for both peak deflection and
area under the curve using a microprocessor-based digital
analyzer (IREX Cardio-80). Peak values are a direct mea-
sure of the brightest echo intensity produced, while area
values additionally reflect the persistence of this optical
brightness over time, or total intensity.
Statistical analysis. Mean values for maximal and in-
tegrated contrast intensity for all experiments were com-
pared for each ultrasonic agent using the Student's t test for
paired data. These values represent the peak intensity and
total intensity produced by a given agent. Reproducibility
of contrast was analyzed by comparing the coefficients of
variation for each agent using the Wilcoxon signed rank
statistic. Heart rate, blood pressure and arterial blood gas
data were analyzed using Student's t test.
Results
One hundred eighty contrast echocardiograms were ob-
tained after peripheral intravenous injection of the five agents
tested, and appeared as clouds of ultrasonic reflectances in
the right atrium and ventricle. Each contrast agent produced
an observable effect that lasted at least several seconds.
Figure 3 shows representative illustrations of the right heart
contrast obtained using SHU-454 and agitated saline solu-
tion in the same animal. The corresponding videodensito-
metric curves obtained from these two injections are shown
in Figure 4.
Comparison of peak and total contrast intensity for
each agent. The peak contrast intensity produced by SHU-
454 (mean 736.5 ± 33.6 mY) was greater than that created
by any other agent for the group of experiments overall, as
well as for each individual animal (Fig. 5). Carbon dioxide
produced slightly higher peak contrast intensity than the
other standard agents, while agitated saline solution produced
the lowest peak values. In regard to area measurements, the
highest values for total intensity were produced with SHU-
454 (76.7 ± 5.4 mV-s) hydrogen peroxide produced the
second greatest magnitude (Fig. 5).
Reproducibility of contrast. The variability of peak and
total contrast intensity was analyzed to determine which
agent yielded the more reproducible opacification under sim-
ilar circumstances in individual animals. SHU-454 consist-
ently demonstrated the lowest coefficient of variation among
the agents (Table I). Thus, SHU-454 was statistically more
reliable (p < 0.004) in producing the highest peak intensity
than the second best agent, carbon dioxide, and was even
more reproducible (p < 0.008) in regard to maximal opa-
cification when compared with the other agents. Indocy-
anine green and agitated saline solution were the least con-
sistent of the agents tested.
SHU-454 was also statistically most reproducible when
comparing total intensity values. It yielded the lowest coef-
ficients of variation when compared with the next most
consistent agent, carbon dioxide (p < 0.04). Hydrogen per-
oxide and agitated saline solution were the least reproducible
agents when comparing total intensity effect (Table I).
Physiologic effects of contrast agents. Heart rates were
calculated from electrocardiographic recordings made dur-
ing and after injection of each agent. These values were
compared with baseline data for each animal. Mean heart
rate during the baseline period was 154 beats/min for the





Figure 3. Two-dimensional echocardio-
grams in the apical four chamber view
comparing peak right heart contrast ob-
tained from SHU-454 (left) and agitated
saline solution (right) in the same animal
and with identical gain settings. The right
heart chambers are more homogeneously
filled after SHU-454 injection. LA = left
atrium; LV = left ventricle.
group of animals, and no significant change in heart rate
occurred with any of the agents. No ectopic beats were
recorded during or after any of the 180 injections. Analysis
of systolic and diastolic blood pressures (mean baseline
192/135 mm Hg) demonstrated a significant decrease (p <
0.0 I) in systolic pressure during carbon dioxide injections.
Because the absolute reduction in blood pressure was only
4 mm Hg, it is unlikely that this alteration is of biologic
significance. There was no significant change in blood pres-
sure with the other agents. Analysis of arterial pH, P02 and
Peo2 (Table 2) revealed no significant changes from baseline
data, except after injection of carbon dioxide. This agent
caused a small (6 mm Hg) but significant decrease in P02
(p < 0.04) as well as a modest (2 mm Hg) and significant
increase in Peo2 (p < 0.03) without affecting pH.
Discussion
Current clinical status. Contrast echocardiography has
achieved a prominent role in the qualitative detection of
intracardiac shunts and tricuspid regurgitation (5-8). How-
ever, attempts at quantitative analysis of contrast echograms
have been restricted by limitations in the reproducibility of
right heart opacification created by standard agents. The
intensity of contrast obtained in the right heart chambers
after venous injection appears to be highly dependent on
the proximity of injection site to the right atrium, cardiac
output, force of injection, amount of hemoglobin present,
the volume of agent and flush solution, bore of the catheter
tip, presence of large bubbles in the gaseous state and the
molecular characteristics of the agents injected (12-14).
Accordingly, it is sometimes difficult or impossible to produce
adequate right heart contrast in individual patients and the
intensity of opacification may vary greatly on consecutive
injections. The results of this study indicate that the new
polysaccharide ultrasonic contrast agent, SHU-454, yields
consistently superior intensity and reproducibility of opa-
cification compared with standard agents utilized.
Mechanism of contrast production. A major consid-
eration in the development of a safe and reliable ultrasonic
agent relates to the mechanism of "microbubble" produc-
tion. Any fluid may produce "targets" of water vapor mi-
crobubbles if injected through a small bore catheter rapidly
enough to result in cavitation (13,15), however, for com-
monly used agents the injection rates necessary to produce
contrast medium by this mechanism may cause vascular
damage, disruption of vein integrity or hemolysis. Meltzer
et al. (14) have shown that the ultrasonic reflectance created
by indocyanine green and agitated saline solution is pri-
SHU-454 NaCI
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Figure 4. Videodensitometric curves ob-
tained after analysis of the SHU-454 and
saline solution injections seen in Figure
3. The polysaccharide contrast agent
produced higher peak intensity for longer
duration.
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Figure 5. Graph showing overall values of peak intensity (left)
and total intensity (right) for the five contrast agents. Each bar
shows the mean and standard error. Note that SHU-454 produced
the highest peak (p < 0.001) and total intensity (p < 0.005) values
when compared with the other agents. ICG = indocyanine green.
marily due to microbubbles of gas produced during mixing
of those agents. Indocyanine green has additional surfactant
properties that tend to stabilize these bubbles at 5 to 15 J.L
diameters and prevent coalescence; however, saline solution
microbubbles tend to coalesce to form much larger and
visible macrobubbles. Other agents such as carbon dioxide
and hydrogen peroxide, produce bubbles by being injected
in the gaseous state. Although carbon dioxide is rapidly
absorbed when used in small doses and can be used safely
(9), it produces large bubbles that may obscure underlying
cardiac anatomy. Intravenous ether in small doses of I to
2 ml produces contrast effects by boiling in the bloodstream
at body temperatures (3). The potential clearly exists for
toxicity when ether is used in higher doses (11).
The experimental right heart contrast agent used in our
study, SHU-454 , is a powder form of a polysaccharide which,
when mixed with a saccharide diluent, forms a suspension
of crystalloid. The crystals have various rhomboid and po-
lyhedral shapes, and range in size from 5 to 10 J.L. A con-
Table 1. Coefficients of Variation*
Peak Intensity Total Intensity
Coefficient of Coefficient of
Agent Variation p Valuet Variation p Valuet
NaCI 28.3 < 0.008 33.6 < 0.008
ICG 25.5 < 0.008 33.6 < 0.008
CO2 18.2 < 0.004 25.9 < 0.04
H2O, 35.5 < 0.008 36.9 < 0.008
SHU-454 6.7 14.3
*Numbers represent mean coefficients of variation for nine dogs. tp values for comparison of SHU-454 with individual standard contrast agents.
CO2 = carbon dioxide; H20 2 = 3% hydrogen peroxide; ICG = indocyanine green; NaCl = 0.9% agitated saline solution; SHU-454 = experimental
polysaccharide contrast agent.





Table 2. Arterial Blood Gases*
Sample Po, Peo, pH
Baseline 98.4 30.0 7.42
NaCI 95.2 29.9 7.43
ICG 98.3 29.2 7.43
CO, n.4t 32.0t 7.41
H,O, 93.6 30.8 7.42
SHU-454 93.8 30.1 7.43
*Mean values for nine dogs expressed in mm Hg. ';'p < 0.04. Abbre-
viations as in Table I.
centration of 350mg/ml was chosen from visual observation
that this dose is optimal for outlining right heart structure
without obliteration of surrounding structures by saturation
of the brightness scale. The precise mechanism by which
SHU-454 produces contrast is not yet defined, by may relate
to the trapping of gas bubbles between the crystals, the
vaporization of water as the material dissolves or even
reflectances from the crystals themselves. Because cavita-
tion is not required, SHU-454 can be injected slowly at rates
less than 1.3 mils and still produce contrast medium. It has
been previously noted (12) that standard agents must be
rapidly injected to achieve maximal contrast effect. Because
the material is organic, it is quickly degraded by common
metabolic pathways. The packaging of material and diluent
in separate containers enables rapid reconstitution of the
solution in a fashion identical to indocyanine green.
Quantitative methodology. Our study is the first to sys-
tematically compare the reproducibility of opacification
produced by the commonly used right heart contrast agents
as well as SHU-454. Care was taken to simulate the clinical
procedure followed for peripheral venous injection. A sim-
ple system of cannula with stopcocks and extension tubing
with plastic syringes was used, similar to previously de-
scribed methods (12) now in widespread use in most echo-
cardiographic laboratories. A reservoir bag was added with
intravenous tubing to allow for purging of the injection lines
without introducing extraneous bubbles. The right ventric-
ular cavity was used as the site for sampling optical density
to avoid mixing and streaming artifacts that may occur in
the right atrium. All injections were done from the foreleg
of the dog to better approximate the clinical setting in which
these agents are used.
Videodensitometry. rather than visual grading. was cho-
sen as the means of quantifying the amount of echo contrast
produced to more objectively and accurately assess the peak
total intensity. This technique is a more precise method for
detecting subtle changes in optical density than is photom-
etry (16). Two potential technical problems that could
interfere with the accuracy of videodensitometry are satu-
ration and linearity. In the present study, care was taken to
choose a dose of each agent that did not saturate the bright-
ness scale of the echograph. Although the ultrasonic device
utilized did not yield a perfectly linear signal relation be-
tween reflected sound and video intensity, previous in vitro
studies have demonstrated that such techniques yield a gen-
eral linearity, and the minor nonlinearity in gray scale al-
location introduced was not thought to be sufficient to in-
fluence the results (16,17).
Superiority of SHU-454 to conventional agents. In our
series, SHU-454 produced higher peak video intensity val-
ues in each animal and had less variable contrast from in-
jection to injection. This reliable, high density opacification
is most likely due to the elimination of several variables
inherent in the process of contrast medium formation, such
as amount of gas trapping, agitation and coalescence. SHU-
454 produces reliable contrast because it is a suspension of
a known concentration of crystals.
The polysaccharide contrast agent also produced large
areas under the videodensitometry curves and a sustained
persistence. Because the duration of contrast visualized in
the right heart with conventional agents is directly related
to the volume of agent and flush used, total volumes were
kept constant in our study. One possible explanation for the
persistence of contrast effect is the slower injection rates
used with SHU-454. With conventional agents, the sub-
stance and flush were delivered as a bolus, while SHU-454
was injected and flushed over a 5 to 7 second period. These
injection rates were chosen as optimal for each individual
agent, to allow for the production of best right heart contrast.
Alternatively, the extended persistence of SHU-454 may be
related to the physicochemical properties of SHU-454 or its
mechanism of contrast production. Such a situation might
provide the basis for structuring ultrasonic agents to have
individual persistence times of advantage for specific
applications.
The polysaccharide nature of SHU-454 was expected to
render it safe and free of alterations in the normal physiology
of the heart and lungs. In our laboratory, there were no
significant acute changes in heart rate, blood pressure, elec-
trocardiogram or arterial blood gases during or after injec-
tion of this agent. Of the standard agents, carbon dioxide
produced the only statistically significant alterations, which
were probably not physiologically important. However, be-
cause SHU-454 is an organic material, the possibility of
delayed or chronic alterations exists, so that further toxicity
studies are planned before SHU-454 is administered to
humans.
Clinical implications. By using standard echographic
recording techniques in combination with videodensito-
metry, a quantitative analysis of contrast intensity can be
performed. We have used such a system to compare the
commonly used echo contrast agents with a new polysac-
charide material, SHU-454. These data demonstrate that
SHU-454 produces more intense and reliable contrast than
conventional right heart contrast agents without evidence of
cardiopulmonary toxicity. This agent holds great promise
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for clinical use in detecting and quantifying intracardiac
shunts and tricuspid regurgitation. In addition, this agent
may prove suitable as an aortic or intracoronary echo con-
trast agent that can be used for the detection of myocardial
perfusion. Further work in these areas is in progress.
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